Tags

Type your tag names separated by a space and hit enter

Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years--United States, 2005-2008.
MMWR Morb Mortal Wkly Rep. 2010 Apr 23; 59(15):456-9.MM

Abstract

Herpes simplex virus type 2 (HSV-2) is one of the most common sexually transmitted infections worldwide and the primary cause of genital and neonatal herpes and genital ulcer disease. Multiple studies have shown that HSV-2 infection increases the risk for human immunodeficiency virus (HIV) infection by at least twofold. HSV-2 infection is lifelong, and serologic testing provides the best method to estimate HSV-2 prevalence. Since 1976, CDC has monitored HSV-2 seroprevalence in the United States through the National Health and Nutrition Examination Survey (NHANES). After increasing from 1976-1980 (NHANES II) to 1988--1994 (NHANES III), HSV-2 seroprevalence decreased, from 21.0% in 1988-1994 to 17.0% in NHANES 1999-2004. To determine whether HSV-2 seroprevalence in the United States has changed since 1999-2004 and to estimate HSV-2 seroprevalence by age, race/ethnicity, and reported lifetime number of sex partners, CDC analyzed serologic test results from persons aged 14-49 years who participated in NHANES 2005-2008. The results indicated that HSV-2 seroprevalence was 16.2% overall, not statistically different from the seroprevalence in 1999-2004. Seroprevalence was highest among women (20.9%) and non-Hispanic blacks (39.2%). Of those infected with HSV-2, 81.1% had not received a diagnosis. Clinicians, health departments, health-care organizations, and community groups should promote measures that prevent HSV-2 transmission, including minimizing the number of sex partners, avoiding concurrent sexual partnerships, and using condoms consistently and correctly. Patients with known HSV-2 infection should be tested for HIV.

Authors

Pub Type(s)

Journal Article

Language

eng

PubMed ID

20414188

Citation

Centers for Disease Control and Prevention (CDC). "Seroprevalence of Herpes Simplex Virus Type 2 Among Persons Aged 14-49 years--United States, 2005-2008." MMWR. Morbidity and Mortality Weekly Report, vol. 59, no. 15, 2010, pp. 456-9.
Centers for Disease Control and Prevention (CDC). Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years--United States, 2005-2008. MMWR Morb Mortal Wkly Rep. 2010;59(15):456-9.
Centers for Disease Control and Prevention (CDC). (2010). Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years--United States, 2005-2008. MMWR. Morbidity and Mortality Weekly Report, 59(15), 456-9.
Centers for Disease Control and Prevention (CDC). Seroprevalence of Herpes Simplex Virus Type 2 Among Persons Aged 14-49 years--United States, 2005-2008. MMWR Morb Mortal Wkly Rep. 2010 Apr 23;59(15):456-9. PubMed PMID: 20414188.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years--United States, 2005-2008. A1 - ,, PY - 2010/4/24/entrez PY - 2010/4/24/pubmed PY - 2010/4/27/medline SP - 456 EP - 9 JF - MMWR. Morbidity and mortality weekly report JO - MMWR Morb Mortal Wkly Rep VL - 59 IS - 15 N2 - Herpes simplex virus type 2 (HSV-2) is one of the most common sexually transmitted infections worldwide and the primary cause of genital and neonatal herpes and genital ulcer disease. Multiple studies have shown that HSV-2 infection increases the risk for human immunodeficiency virus (HIV) infection by at least twofold. HSV-2 infection is lifelong, and serologic testing provides the best method to estimate HSV-2 prevalence. Since 1976, CDC has monitored HSV-2 seroprevalence in the United States through the National Health and Nutrition Examination Survey (NHANES). After increasing from 1976-1980 (NHANES II) to 1988--1994 (NHANES III), HSV-2 seroprevalence decreased, from 21.0% in 1988-1994 to 17.0% in NHANES 1999-2004. To determine whether HSV-2 seroprevalence in the United States has changed since 1999-2004 and to estimate HSV-2 seroprevalence by age, race/ethnicity, and reported lifetime number of sex partners, CDC analyzed serologic test results from persons aged 14-49 years who participated in NHANES 2005-2008. The results indicated that HSV-2 seroprevalence was 16.2% overall, not statistically different from the seroprevalence in 1999-2004. Seroprevalence was highest among women (20.9%) and non-Hispanic blacks (39.2%). Of those infected with HSV-2, 81.1% had not received a diagnosis. Clinicians, health departments, health-care organizations, and community groups should promote measures that prevent HSV-2 transmission, including minimizing the number of sex partners, avoiding concurrent sexual partnerships, and using condoms consistently and correctly. Patients with known HSV-2 infection should be tested for HIV. SN - 1545-861X UR - https://www.unboundmedicine.com/medline/citation/20414188/Seroprevalence_of_herpes_simplex_virus_type_2_among_persons_aged_14_49_years__United_States_2005_2008_ L2 - https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5915a3.htm DB - PRIME DP - Unbound Medicine ER -